Stockreport

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc.  (ANRO) 
PDF – Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by e [Read more]